CFRXQ
CONTRAFECT CORP by ContraFect Corporation (CFRXQ)
$00
About CONTRAFECT CORP by ContraFect Corporation (CFRXQ)
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Details
Daily high
$0.00
Daily low
$0.00
Price at open
--
52 Week High
$0.00
52 Week Low
$0.00
Market cap
1,100
Dividend yield
0.00%
Volume
64
Avg. volume
1
P/E ratio
--
CONTRAFECT CORP by ContraFect Corporation News
Details
Daily high
$0.00
Daily low
$0.00
Price at open
--
52 Week High
$0.00
52 Week Low
$0.00
Market cap
1,100
Dividend yield
0.00%
Volume
64
Avg. volume
1
P/E ratio
--